Chikungunya virus vaccines: Current strategies and prospects for developing plant-made vaccines. (Q38527379)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26073010%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

review article

1 reference

title

Chikungunya virus vaccines: Current strategies and prospects for developing plant-made vaccines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26073010%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

0 references

1 reference

Jorge A Salazar-González

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26073010%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

Carlos Angulo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26073010%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Sergio Rosales-Mendoza

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26073010%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

language of work or name

English

0 references

publication date

12 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26073010%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26073010%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26073010%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26073010%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

3650-3658

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26073010%20AND%20SRC:MED&resulttype=core&format=json

A destructive arthropathy following Chikungunya virus arthritis--a possible association

17 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Reemergence of Chikungunya virus in Cambodia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Reemergence of chikungunya virus in Bo, Sierra Leone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Chikungunya in the Americas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Update on emerging infections: news from the Centers for Disease Control and Prevention. Notes from the field: chikungunya virus spreads in the Americas-Caribbean and South America, 2013-2014.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

A single mutation in chikungunya virus affects vector specificity and epidemic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

On chikungunya acute infection and chloroquine treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in vero cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Prophylaxis and therapy for Chikungunya virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

An essential role of antibodies in the control of Chikungunya virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Inhibition of herpes simplex virus multiplication by the pokeweed antiviral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Inhibition of Japanese encephalitis virus infection in vitro and in vivo by pokeweed antiviral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Inhibitory effects of a peptide-fusion protein (Latarcin-PAP1-Thanatin) against chikungunya virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Chikungunya virus arthritis in adult wild-type mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Serum IL-18 and IL-18BP levels in patients with Chikungunya virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Chikungunya virus and prospects for a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Development of an attenuated strain of chikungunya virus for use in vaccine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Immunologic interference from sequential administration of live attenuated alphavirus vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Chimeric alphavirus vaccine candidates for chikungunya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Transmission potential of two chimeric Chikungunya vaccine candidates in the urban mosquito vectors, Aedes aegypti and Ae. albopictus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Prime-boost immunization strategies against Chikungunya virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Alphavirus-based expression vectors: strategies and applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Effective chikungunya virus-like particle vaccine produced in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Enhanced production of Chikungunya virus-like particles using a high-pH adapted spodoptera frugiperda insect cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Comparative pathogenesis of epidemic and enzootic Chikungunya viruses in a pregnant Rhesus macaque model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

A nonhuman primate model of chikungunya disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Current status of viral expression systems in plants and perspectives for oral vaccines development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Magnifection--a new platform for expressing recombinant vaccines in plants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

In planta production of plant-derived and non-plant-derived adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Virus-like particles produced in plants as potential vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Novel vaccination approach for dengue infection based on recombinant immune complex universal platform

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Oral delivery of bioencapsulated proteins across blood-brain and blood-retinal barriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Plant-made vaccine antigens and biopharmaceuticals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Plant-specific glycosylation patterns in the context of therapeutic protein production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Molecular basis of N-acetylglucosaminyltransferase I deficiency in Arabidopsis thaliana plants lacking complex N-glycans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Posttranslational modification of therapeutic proteins in plants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Immunization with immune complex alters the repertoire of antigen-reactive B cells in the germinal centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

The immune complex: possible ways of regulating the antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Highly immunogenic and protective recombinant vaccine candidate expressed in transgenic plants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Plant-derived recombinant immune complexes as self-adjuvanting TB immunogens for mucosal boosting of BCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Large-scale extraction of proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Elastin-like polypeptides revolutionize recombinant protein expression and their biomedical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

ELPylated haemagglutinins produced in tobacco plants induce potentially neutralizing antibodies against H5N1 viruses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

A Plant-Derived Multi-HIV Antigen Induces Broad Immune Responses in Orally Immunized Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Immunogenic properties of a lettuce-derived C4(V3)6 multiepitopic HIV protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Expression of Multiple Taenia Solium Immunogens in Plant Cells Through a Ribosomal Skip Mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

A plant-based multicomponent vaccine protects mice from enteric diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

The mucosal immune system for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Immunological aspects of using plant cells as delivery vehicles for oral vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Is an oral plant-based vaccine against hepatitis B virus possible?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Automated production of plant-based vaccines and pharmaceuticals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Advances and challenges in the development and production of effective plant-based influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Immunogenicity of H1N1 influenza virus-like particles produced in Nicotiana benthamiana.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Agrobacterium-mediated transient expression as an approach to production of recombinant proteins in plants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Chloroplast vector systems for biotechnology applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

Plant-based vaccines against viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.104

10.1016/J.VACCINE.2015.05.104

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26073010%20AND%20SRC:MED&resulttype=core&format=json

release_4pmztnpzjvhrnfsn6lo5uhmtye

17 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4pmztnpzjvhrnfsn6lo5uhmtye

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26073010%20AND%20SRC:MED&resulttype=core&format=json